Biochemical effects of calcium supplementation in postmenopausal women: influence of dietary calcium intake

Fardellone, Patrice; Brazier, Michel; Kamel, Saı̈d; Guéris, J; Graulet, AM; Liénard, Jean‐Sylvain; Sébert, J. L.

doi:10.1093/ajcn/67.6.1273

Cited by 66 publications

(36 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Osteocalcin is involved in bone calcification; hence its level may be lowered after therapy. Our findings were also supported by the study of Johannes et al [8], Ones et al [9], Sambrook et al [16] and Fardellone et al [17].…”

Section: Resultssupporting

confidence: 92%

BMD and Serum Intact Osteocalcin in Postmenopausal Osteoporosis Women

2010

View full text Add to dashboard Cite

India seems to have the highest prevalence of osteoporosis. With growing awareness of osteoporosis and its impact on life span especially in India, special attention is being paid to early detection, management and treatment of postmenopausal osteoporosis in women. Measurement of BMD and osteocalcin are of value in estimating bone turnover rates. The aim of this study is (1) to measure the specific, sensitive bone formation marker such as osteocalcin and BMD in postmenopausal osteoporosis women and postmenopausal non-osteoporosis women; (2) the follow up study to evaluate the impact of specific antiresorptive therapy (alendronate ? calcium ? vitamin D) regimen in postmenopausal osteoporosis by assaying osteocalcin and BMD. Sixty clinically diagnosed postmenopausal osteoporosis patients and 60 normal subjects (postmenopausal non-osteoporosis women) were recruited as control. Mean bone mineral density T score and Z score was significantly decreased (P \ 0.001) in postmenopausal osteoporosis patients as compared to controls. Highly significant increase in the mean score of BMD-T score and Z score from baseline to post therapy of 3 months was observed in postmenopausal osteoporosis women. Serum osteocalcin levels were significantly increased (P \ 0.001) as compared to control group. Serum osteocalcin levels were decreased significantly (P \ 0.001) from baseline to post therapy of 3 months in postmenopausal osteoporosis women. BMD is the best quantifiable predictor of osteoporotic fracture and osteocalcin is specific, sensitive, promising, currently used marker for better prognosis of osteoporosis and for monitoring responses to antiresorptive therapy.

show abstract

Section: Resultssupporting

confidence: 92%

BMD and Serum Intact Osteocalcin in Postmenopausal Osteoporosis Women

2010

View full text Add to dashboard Cite

show abstract

“…Reduction in bone loss during antiresorptive treatment is demonstrated by decreased excretion of hydroxyproline post antiresorptive therapy. Our findings were also supported by Fardellone et al [17], Kamel et al [18], and Horowitz et al [19] and will definitely aid the orthopaedicians of Western Maharashtra to monitor collagen and bone metabolism and better management of PMO.…”

Section: Resultssupporting

confidence: 87%

Effect of Antiresorptive Therapy on Urinary Hydroxyproline in Postmenopausal Osteoporosis

Jagtap

Ganu

2011

Ind J Clin Biochem

View full text Add to dashboard Cite

Osteoporosis becomes a serious health threat for older postmenopausal women by predisposing them to an increased risk of fracture. Osteoporosis and associated fractures are an important cause of morbidity and mortality. Special attention is being paid to early detection, management, and treatment of postmenopausal osteoporosis in women. Biochemical markers can enable dynamic and rapid measurement of total body skeletal metabolism and will be clinically useful in the management of postmenopausal osteoporosis women (PMO) and also for assessing the effects of antiresorptive therapy. With this view, we planned to assess osteoclastic activity by determining urinary hydroxyproline in osteoporotic women. The aim of this study is to measure urinary hydroxyproline (expressed as mg of hydroxyproline/g of creatinine) and serum ascorbic acid in postmenopausal women with osteoporosis and without osteoporosis. These biochemical parameters were determined 3 months post antiresorptive therapy (alendronate ? calcium ? vitamin D) in postmenopausal osteoporosis patients. 60 postmenopausal women with osteoporosis in the age group 45-60 years and 60 healthy postmenopausal women (normal bone mineral density) in the same age group were included in the study. Urinary hydroxyproline levels were significantly increased (P \ 0.001) in PMO at baseline level as compared to control group. These levels were decreased significantly (P \ 0.001) post therapy in PMO patients. Serum vitamin C levels were significantly decreased (P \ 0.001) in PMO patients at baseline level as compared to controls. No significant change occurred of serum vitamin C level post therapy. Raised excretion of hydroxyproline at the baseline level might be due to increased degradation of collagen type I from the bone matrix in osteoporosis. Breakdown of collagen seems to be lowered as reflected by lowering of hydroxyproline excretion post antiresorptive therapy. Alteration in the concentration of this marker can be very well utilized to monitor the effectiveness of therapy. Thus simple, direct urinary assay to measure bone resorption is very useful in monitoring the therapy in PMO and may become an integral part of the management of osteoporosis.

show abstract

“…In contrast, studies of calcium supplementation in postmenopausal women, typically of 1 to 2 y in duration, have shown that calcium cannot prevent bone loss, but can reduce the rate of bone loss to some extent ( 1 ). Calcium supplementation results in increased urinary calcium excretion with a reduction of PYR and DPD in postmenopausal women ( 33 ). In our study, the BMD of the lumbar spine did not differ between the LS and maltose groups at 96 wk, and the BMD of the lumbar spine in the LS group did not change compared to week 0 ( Table 1).…”

Section: Discussionmentioning

confidence: 41%

Long-Term Administration of 4G-.BETA.-D-Galactosylsucrose (Lactosucrose) Enhances Intestinal Calcium Absorption in Young Women: A Randomized, Placebo-Controlled 96-wk Study

Teramoto

Rokutan

Sugano

et al. 2006

J Nutr Sci Vitaminol

View full text Add to dashboard Cite

SummaryThis study determined the effect of long-term administration of 4 G -␤ -D -galactosylsucrose (lactosucrose; LS) on intestinal calcium absorption. In a randomized, singleblind, parallel-group study, LS ( n ϭ 9, 6.0 g twice daily) or a placebo (maltose; n ϭ 8, 6.0 g twice daily) was administered to healthy young women for 92 wk; the study also included a 4-wk post-administration period. All participants completed the study. Dietary nutrient intake; fecal weight, pH, and moisture content; fecal concentrations of short-chain fatty acids (SCFA), putrefactive products, ammonia, and minerals (calcium, magnesium, phosphorus, and iron); and serum calcium and osteocalcin concentrations were measured every 24 wk. Urinary pyridinoline (PYR) and deoxypyridinoline (DPD), and urinary calcium excretion were measured every 12 wk. Significant effects of oligosaccharide treatment, time, and the interaction between oligosaccharide treatment and time were observed for fecal pH, SCFA, ammonia, and putrefactive product values ( p Ͻ 0.05). Fecal pH, ammonia, and putrefactive product values decreased in the LS group, and the fecal SCFA concentration significantly increased during the administration period; these changes were not observed 4 wk post-administration. To examine the mineral balance of calcium, magnesium, and phosphorus in detail, all the participants completed a 6-d mineral balance study, sometime between week 56 and 60 of the longer study. During the mineral balance study, the daily calcium intake was set at 400 mg; all feces and urine were collected each day for 6 d after an 8-d acclimation period. In the balance study, fecal calcium excretion was significantly lower in the LS group than in the placebo group ( p Ͻ 0.05), and apparent calcium absorption and retention, apparent magnesium and phosphorus absorption, and magnesium retention were significantly higher in the LS group than in the placebo group ( p Ͻ 0.05). Our results suggest that the administration of LS produces a long-term enhancement of intestinal calcium absorption in healthy young women with lower than recommended calcium intakes. Key Words fecal pH, fecal short-chain fatty acids, intestinal calcium absorption, lactosucrose, young healthy women Calcium is an essential component of bone, and insufficient calcium intake may cause weakened bones, especially in women who are prone to osteoporosis. Bone mass in later life depends on the peak bone mass (PBM) achieved during growth and the rate of subsequent age-related bone loss ( 1 ). Bone mineral is laid down throughout childhood, with the most rapid increase occurring during puberty. The deposition continues, though at a slower rate, after growth in height has stopped ( 2 ). PBM is achieved in early adult life (20-35 y of age), although the exact timing is not certain and may vary in different parts of the skeleton ( 3 ). The calcium intake in young Japanese women is lower than the recommended calcium intake ( 4 -6 ). Thus, these women are at risk of future osteoporosis resulting from insufficient calciu...

show abstract

Biochemical effects of calcium supplementation in postmenopausal women: influence of dietary calcium intake

Cited by 66 publications

References 30 publications

BMD and Serum Intact Osteocalcin in Postmenopausal Osteoporosis Women

BMD and Serum Intact Osteocalcin in Postmenopausal Osteoporosis Women

Effect of Antiresorptive Therapy on Urinary Hydroxyproline in Postmenopausal Osteoporosis

Long-Term Administration of 4G-.BETA.-D-Galactosylsucrose (Lactosucrose) Enhances Intestinal Calcium Absorption in Young Women: A Randomized, Placebo-Controlled 96-wk Study

Contact Info

Product

Resources

About